

PRODUCT INFORMATION



Bepridil (hydrochloride)

Item No. 19645

CAS Registry No.: 68099-86-5
Formal Name: β -[[2-methylpropoxy)methyl]-
N-phenyl-N-(phenylmethyl)-
1-pyrrolidineethanamine,
monohydrochloride

MF: C₂₄H₃₄N₂O • HCl
FW: 403.0


Purity: $\geq 98\%$

UV/Vis.: λ_{\max} : 248, 295 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Bepridil (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the bepridil (hydrochloride) in the solvent of choice. Bepridil (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of bepridil (hydrochloride) in these solvents is approximately 25, 5, and 20 mg/ml, respectively.

Bepridil (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, bepridil (hydrochloride) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Bepridil (hydrochloride) has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Bepridil is a dihydropyridine that has anti-anginal and anti-arrhythmic actions by blocking calcium channels in heart and smooth muscle.^{1,2} It is recognized as a non-selective channel blocker, altering myocardial Ca²⁺, Na⁺, and K⁺ currents.³ For example, it blocks voltage-gated Ca²⁺ (Ca_v3.2) and K⁺ (hERG and KCNQ4) channels, sarcoplasmic ATP-sensitive K⁺ (K_{ATP}) channels, and Na⁺-activated (K_{Na}) channels (IC₅₀s = 7.1, 22, 9.4, 10, and 2.2 μ M, respectively).^{2,4-6} It also activates mitochondrial K_{ATP} channels (ED₅₀ = 27.5 μ M).⁷

References

1. Singh, B.N. *Br. J. Clin. Pharmacol.* **21**, 109S-121S (1986).
2. Perez-Reyes, E., Van Deusen, A.L., and Vitko, I. *J. Pharmacol. Exp. Ther.* **328**(2), 621-627 (2009).
3. Iijima, K., Chinushi, M., Izumi, D., et al. *Circ. J.* **74**(5), 895-902 (2010).
4. Sinha, N. and Sen, S. *Eur. J. Med. Chem.* **46**(2), 618-630 (2011).
5. Sogaard, R., Ljungstrom, T., Pedersen, K.A., et al. *Am. J. Physiol. Cell Physiol.* **280**(4), C859-C866 (2001).
6. Li, Y., Sato, T., and Arita, M. *J. Pharmacol. Exp. Ther.* **291**(2), 562-568 (1999).
7. Sato, T., Costa, A.D.T., Saito, T., et al. *J. Pharmacol. Exp. Ther.* **316**(1), 182-188 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/29/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM